c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH

Experimental and Molecular Pathology

Volumn 66, Issue 2, 1999, Pages 140-148

  Wang, Zong Ren ^a   Liu, Weihua ^a   Smith, S Terrell ^a   Parrish, Rudolph S ^a   Young, S Robert ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CENTROMERE; CHROMOSOME 8; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; ONCOGENE C MYC; ONCOGENE NEU; OVARY CANCER; PROGNOSIS; SURVIVAL RATE;

EID: 0032793672     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.1999.2259     Document Type: Article

References (41)

1. Afify A., Mark H. F. L. Fluorescence in situ hybridization assessment of chromosome 8 copy number in stage I and stage II infiltrating ductal carcinoma of the breast. Cancer Genet. Cytogenet. 97:1997;101-105.
2. Afify A., Brown S., Samy M., Sun C. L., Santoro S., Mark H. F. L. Trisomy 8 in embryonal rhabdomyosarcoma detected by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 108:1999;127-132.
3. Augenlicht L. H., Wadler S., Corner S., Richards C., Ryan L., Multani A. S., Pathak S., Benson A., Haller D., Heerdt B. G. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: A frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res. 57:1997;1769-1775.
4. Barnard D. R., Kalousek D. K., Wiersma S. R., Lange B. J., Benjamin D. R., Arthur D. C., Buckley J. D., Kobrinsky N., Neudorf S., Sanders J., Miller L. P., Shina D. C., Hammond G. D., Woods W. G. Morphologic, immunologic, and cytogenetic classification of acute myeloid leukemia and myelodysplastic syndrome in childhood: A report from the Children's Cancer Group. Leukemia. 10:1996;5-12.
5. Berchuck A. Biomarkers in the ovary. J. Cell. Biochem. Suppl. 23:1995;223-226.
6. Berns E. M., Klijn J. G., van Putten W. L., van Staveren H., Portengen H., Foekens J. A. C-myc amplification is a better prognostic factor than HER-2/neu amplification in primary breast cancer. Cancer Res. 52:1992;1107-1113.
7. Bian M., Fan Q., Huang S., Ma J., Lang J. Amplifications of proto-oncogenes in ovarian carcinoma. Chin. Med. J. Engl. 108:1995;844-848.
8. Bullerdiek J., Leuschner E., Taquia E., Bonk U., Bartnitzke S. Trisomy 8 as a recurrent clonal abnormality in breast cancer. Cancer Genet. Cytogenet. 65:1993;64-67.
9. Chattopadhyay S., Marinduque B., Gilbert F. Ovarian cancer: Protocol for the preparation of banded metaphase from tumor tissue. Cancer Genet. Cytogenet. 59:1992;210-212.
10. Csokay B., Papp J., Besznyak I., Bosze P., Sarosi Z., Toth J., Zalay Z., Olah E. Oncogene patterns in breast and ovarian carcinomas. Eur. J. Surg. Oncol. 19:1993;593-599.
11. Davey F. R., Abraham N. Jr., Brunetto V. L., MacCallum J. M., Nelson D. A., Ball E. D., Griffin J. D., Baer M. R., Wurster-Hill D., Mayer R. J. Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): A CALGB study. Am. J. Hematol. 49:1995;29-38.
12. Escot C., Theillet C., Lidereau R., Spyratos F., Champeme M. H., Gest J., Callahan R. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc. Natl. Acad. Sci. USA. 83:1986;4834-4838.
13. Fujimoto I., Shimizu Y., Umezawa S., Katase K., Hirai Y., Yamauchi K., Hasumi K. Studies on the point mutation of rasoncogene in ovarian tumor. Nippon Sanka Fujinka Gakkai Zasshi. 45:1993;1289-1296.
14. Iguchi-Ariga S. M. M., Kijim Y., Ariga H. Possible function of the c-myc product: Promotion of cellular DNA replication. EMBO J. 6:1987;2365-2371.
15. Jenkins R. B., Qian J., Lieber M. M., Bostwick D. G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 75:1997;524-531.
16. Kallioniemi O.-P., Kallioniemi A., Kurisu W., Thor A., Chen L.-C., Smith H. S., Walkman F. M., Pinkel D., Gray J. W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl. Acad. Sci. USA. 89:1992;5321-5325.
17. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53:1958;457-481.
18. Kataoka A., Yakushiji M., Kojiro M. A study of amplifications of myc gene (c-myc and N myc) in human ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi. 42:1990;259-263.
19. Katsaros D., Theillet C., Zola P., Louason G., Sanfilippo B., Isaia E., Arisio R., Giardina G., Sismondi P. Concurrent abnormal expression of erbB-2, myc, and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res. 15:1995;1501-1510.
20. Lachman H. M., Skoultchi A. I. Expression of c-myc changes during differentiation of mouse erythroleukemia cell. Nature (London). 310:1984;592-594.
21. Liu, W.-H, Brock, J. K, Smith, T. S, and, Young, S. R. (, 1995, ), Oncogene amplification and tumor suppressor gene detection in ovarian cancer, In, "48th Annual Symposium on Fundamental Cancer Research, Houston," p, 116.
22. Lu Y., Cheng S., Guo S. Detection of c-myc translocation in human lung cancer cells by fluorescence in situ hybridization (FISH). Chung Hua I Hsueh Tsa Chih. 75:1995;214-215.
23. Lu Y., Cheng S., Guo S. C-myc activation by translocation in human primary non-small cell lung cancer. Chung Hua I Hsueh Tsa Chih. 76:1996;275-277.
24. Makino R., Hayashi K., Sugimura T. C-myc transcript is induced in rat liver at a very early stage of regeneration by cycloheximide treatment. Nature (London). 310:1984;697-698.
25. Mark H. F. L., Afify A., Taylor W., Santoro K., Lathrop J. C. A subset of gestational trophoblastic disease characterized by abnormal chromosome 8 copy number detected by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 99:1997;24-29.
26. Mark H. F. L., Taylor W., Afify A., Riera D., Rausch M., Huth A., Gray Y., Santoro K., Bland K. I. Stage I and stage II nfiltrating ductal carcinoma of the breast analyzed for chromosome 8 copy number using FISH. Pathobiology. 65:1998;184-189.
27. Mark H. F. L., Taylor W., Afify A., Brown S., Samy M., Sun C. L., Santoro K., Bland K. I. Chromosome 8 copy number in stage I and stage IV infiltrating ductal carcinoma of the breast studied using interphase FISH. Cancér Genet. Cytogenet. 108:1999;1-5.
28. Meyers S. L., O'Brien M. T., Smith T., Dudley J. P. Analysis of the int 1, int 2, c-myc, and neu oncogenes in human breast carcinomas. Cancer Res. 50:1990;5911-5918.
29. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer Statistics. CA Cancer J. Clin. 47:1997;5-27.
30. Perkins D., Brennan S., Carstairs K., Bailey D., Pantalony D., Poon A., Fernandes B., Dube I. Regional cancer cytogenetics: a report on 1,143 diagnostic cases. Cancer Genet. Cytogenet. 96:1997;64-80.
31. Press M. F., Bernstein L., Thomas P. A., Meisner L. F., Zhou J. Y., Ma Y., Hung G., Robinson R. A., Harris C., El-Naggar A., Slamon D. J., Phillips R. N., Ross J. S., Wolman S. R., Flom K. J. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15:1997;2894-2904.
32. Sato T., Abe K., Kurose A., Uesugi N., Todoroki T., Sasaki K. Amplification of the c-erbB-2 gene detected by FISH in gastric cancers. Pathol. Int. 47:1997;179-182.
33. Sauter G., Moch H., Moore D., Carroll P., Kerschmann R., Chew K., Mihatsch M. J., Judat F., Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53:1993;2199-2203.
34. Schmid P., Schulz W. A., Hameister H. Dynamic expression pattern of the c-myc protooncogene in midgestation mouse embryos. Science. 243:1989;226-229.
35. Tashiro H., Miyazaki K., Okamura H., Iwai A., Fukumoto M. c-myc over expression in human primary ovarian tumours: Its relevance to tumour progression. Int. J. Cancer. 50:1992;828-833.
36. van Dam P. A., Vergote I. B., Lowe D. G., Watson J. V., van Damme P., van der Auwera J. C., Shepherd J. H. Expression of c-erbB-2, c-myc, and c ras oncoproteins, insulin like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J. Clin. Pathol. 47:1994;914-919.
37. Varley J. M., Swallow J. E., Brammar W. J., Whittaker J. L., Walker R. A. Alterations to either c-erbB-2(neu) or c-myc proto oncogenes in breast carcinomas correlate with poor short term prognosis. Oncogene. 1:1987;423-430.
38. Veronese M. L., Ohta M., Finan J., Nowell P. C., Croce C. M. Detection of myc translocations in lymphoma cells by fluorescence in situ hybridization with yeast artificial chromosomes. Blood. 85:1995;2132-2138.
39. Visscher D. W., Wallis T., Awussahm S., Mohamedm A., Crissman J. D. Evaluation of MYC and chromosome 8 copy number in breast carcinoma by interphase cytogenetics. Genes Chromosomes Cancer. 18:1997;1-7.
40. Xin X. Y. The amplification of c-myc, N-ras, c-erbB-2 oncogenes in ovarian malignancies. Chung Hua Fu Chan Ko Tsa Chih. 28:1993;405-407.
41. Young S. R., Liu W.-H., Brock J. A., Smith S. T. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer. 16:1996;130-137.